Citizen Petition from Covington & Burling LLP on Behalf of Novo Nordisk Inc.

Holly Anderson, a private individual, supports the petition by advocating for 503B compounding pharmacies to have access to GLP-1 drugs. She argues that these pharmacies provide essential, affordable access to medications like semeglutide and tirzepatide for patients who cannot afford the brand-name versions.

The commenter opposes the proposed action, arguing that it is designed to protect the profits of large corporations rather than public health. They claim the measure will restrict access to cheaper, out-of-pocket compounding medications in favor of more expensive "name brand" services controlled by insurance companies.